Liu May-Lan, Liu Pang-Yen, Chao Louis Kuoping, Yang Tzu-Jung, Li Lan-Hui, Weng Yih-Ming, Sommano Sarana Rose, Unpaprom Yuwalee, Ramaraj Rameshprabu, Ho Chen-Lung, Hua Kuo-Feng
Department of Food Science, National Chiayi University, Chiayi 600355, Taiwan.
Department of Early Childhood Educare, WuFeng University, Chiayi 621303, Taiwan.
Int J Mol Sci. 2025 Jun 5;26(11):5419. doi: 10.3390/ijms26115419.
Inflammation is a vital physiological response that plays a crucial role in regulating host defense against pathogens while maintaining tissue homeostasis. Inflammasomes, a family of protein complexes, are responsible for controlling the expression of pro-inflammatory cytokines IL-1β and IL-18, and they play significant roles in inflammatory responses. However, dysregulated inflammation can become a risk factor for the pathogenesis of various diseases. The discovery of anti-inflammatory substances derived from natural products represents an important strategy for new drug development. In this study, we found that the essential oil derived from the heartwood of Hayata (EOC) exhibits anti-inflammatory activities by inhibiting the NLRP3, NLRP1, NLRC4, AIM2, and non-canonical inflammasomes in macrophages. EOC also suppresses the expression of NLRP3, TNF-α, IL-6, and NO in LPS-activated macrophages. The mechanisms underlying the anti-inflammatory activity of EOC were shown to involve a reduction in reactive oxygen species production and NF-κB activation. Furthermore, terpinen-4-ol may be the key anti-inflammatory compound present in EOC. These results suggest that EOC has potential as an anti-inflammatory agent for future development.
炎症是一种重要的生理反应,在调节宿主对病原体的防御以及维持组织内环境稳定方面发挥着关键作用。炎性小体是一类蛋白质复合物家族,负责控制促炎细胞因子白细胞介素-1β(IL-1β)和白细胞介素-18(IL-18)的表达,并且在炎症反应中发挥重要作用。然而,炎症失调会成为各种疾病发病机制的一个危险因素。从天然产物中发现抗炎物质是新药开发的一项重要策略。在本研究中,我们发现玉山黄肉楠心材精油(EOC)通过抑制巨噬细胞中的NLRP3、NLRP1、NLRC4、AIM2和非经典炎性小体而表现出抗炎活性。EOC还能抑制脂多糖激活的巨噬细胞中NLRP3、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和一氧化氮(NO)的表达。EOC抗炎活性的潜在机制显示涉及活性氧生成减少和核因子-κB(NF-κB)激活。此外,萜品-4-醇可能是EOC中存在的关键抗炎化合物。这些结果表明EOC有潜力作为一种抗炎剂用于未来开发。
Inflammopharmacology. 2025-4-9
Front Immunol. 2023
Int J Mol Med. 2025-3
Sci Transl Med. 2023-11-22
Biomolecules. 2023-7-18
J Toxicol Environ Health A. 2023-7-18
Annu Rev Immunol. 2023-4-26